Acebrophylline: an airway mucoregulator and anti-inflammatory agent

E. Pozzi


Acebrophylline is an airway mucus regulator with anti-inflammatory action. The drug’s approach involves several points of attack in obstructive airway disease. The molecule contains ambroxol, which facilitates various steps in the biosynthesis of pulmonary surfactant, theophylline-7-acetic acid whose carrier function raises blood levels of ambroxol, thus rapidly and intensely stimulating surfactant production. The resulting reduction in the viscosity and adhesivity of the mucus greatly improves ciliary clearance. By deviating phosphatidylcholine towards surfactant synthesis, making it no longer available for the synthesis of inflammatory mediators such as the leukotrienes, acebrophylline also exerts an inflammatory effect. This is confirmed in vivo by the reduction in specific bronchial hyper-responsiveness in patients with stable bronchial asthma.

On a clinical level, acebrophylline is therapeutically effective in patients with acute or chronic bronchitis, chronic obstructive or asthma-like bronchitis; it reduces the frequency of episodes of bronchial obstruction and reduces the need for \( \beta_2 \)-agonists, and improves indexes of ventilatory function. 


Keywords: Acebrophylline, ambroxol, alveolar surfactant, airway hyper-responsiveness, chronic bronchitis, asthma-like bronchitis.

Pulmonary Diseases Department, IRCCS San Matteo, University of Pavia, Italy.

Correspondence: Ernesto Pozzi, Pulmonary Diseases Department, IRCCS San Matteo, Via Taramelli 5, 27100 Pavia, Italy; e-mail: ernesto.pozzi@unipv.it

Introduction

International preclinical and clinical literature acknowledges that airway mucus stasis and lack of surfactant are bound in a reciprocal causal relationship: by stimulating phospholipid synthesis one can act on the mucus stasis [1, 2]. The phospholipids also serve as precursors for inflammatory mediators in the etiopathogenesis and maintenance of the chronic processes underlying chronic obstructive lung disease (COLD). There is a metabolic pathway common to pulmonary surfactant and to the leukotrienes LTB4, LTC4, LTD4 and LTE4 [3, 4]; it is therefore logical to assume that a drug such as acebrophylline, which partially inhibits phospholipase A [5], should not only influence the rheological properties of the mucus, facilitating its removal from the airways, but should also have “anti-inflammatory/antireactive” action, driving synthesis towards metabolites such as surfactant, with a physiological action in the patient rather than those with negative effects, like the leukotrienes [6].

A qualitative or quantitative lack of surfactant can in fact play a pathogenic role in bronchospasm, as reported by Enhorning et al. [7] and is confirmed by:

• epidemiological studies that report a higher incidence of bronchial asthma developing in premature babies, with their obvious lack of surfactant [8];
• the description of interactions between surfac-
Pharmacological research has focused on finding easier-to-handle molecules with dual action: bronchsectrolytic on the one hand, and stimulating the synthesis and release of pulmonary surfactant on the other, with ambroxol heading this last group [20].

Against this backdrop the compound acebrophylline has been developed and clinically tested; this is a natural pharmacological step forward from ambroxol, stimulating the production of pulmonary surfactant more promptly and strongly and ideal for use in children and adults. Not only does it improve the rheology of bronchial mucus and its transport, but it also controls bronchial hyperresponsiveness more directly, through a multifactorial approach.

**Chemical/physical properties of acebrophylline**

Acebrophylline is obtained by targeted salification of the ambroxol base [trans-4(2-amino-3,5 dibromobenzylamino) cyclohexanol] and theophylline 7 acetic acid. The carboxyl group of theophylline 7 acetic acid was salified with ambroxol’s amine group in a stoichiometric ratio (38.7% acid and 61.3% base) that ensures, after absorption, high plasma levels of ambroxol with low levels of the xanthine derivative which are nevertheless high enough to ensure a carrier effect for ambroxol [21]. This means that one hour after administration lung levels of ambroxol are 45% higher than in subjects treated with ambroxol alone.

**Mechanism of action**

Studies have looked at the combined action of the two components of acebrophylline on the production of pulmonary surfactant and the benefits with regard to mucus regulation and mucokinetics, and the anti-inflammatory-antireactive action essential for clearing bronchial obstruction.

### 1) Synthesis and release of pulmonary surfactant

Surfactant production in the rat was compared, in terms of levels of total phospholipids and phosphatidylcholine in BAL after five days’ treatment with acebrophylline, and in an untreated control group. An increase in the surfactant phospholipid matrix was evident just two hours after the last dose, and the rise was significantly greater in the treated group (161±11 mcg/mL) than in controls (139±3.6 mcg/mL) about 18 hours after the last dose [22] (fig. 1).

In order to assess the mechanism by which acebrophylline stimulates pulmonary surfactant synthesis and release, the drug’s effect was investigated on the uptake of labeled surfactant precursors in rat lung slices, in order to see how much the tissue was stimulated to produce surfactant [22].

The uptake of 14C-choline, one of the precursors of phosphatidylcholine was compared with that of 32P-phosphate, a phospholipid precursor, in rats treated for five days with acebrophylline, or its components singly: ambroxol and theophylline 7 acetic acid. Compared to controls 14C-choline uptake in phosphatidylcholine was significantly higher after acebrophylline and ambroxol; theophylline 7 acetic acid also tended to increase uptake but not significantly. With 32P-phosphate acebrophylline increased uptake significantly more than controls, which had the same effect as ambroxol; again, theophylline-7 acetic acid tended to increase uptake, but not significantly (fig. 2).

The fact that acebrophylline induced the uptake not only of labeled choline but also of 32P-phosphate suggests it acts on two levels on surfactant synthesis: the first involves ambroxol’s estab-

---

![Fig. 1. - Effect of acebrophylline on the components of alveolar surfactant in rats.](image-url)
lished action on phosphocholine-cytidyl-transferase [25, 26] and the second probably because of theophylline-7 acetic acid’s action on choline-kinase [22] (fig. 3).

In cultured type II pneumocytes from rabbit BAL exposed to acebrophylline or equivalent doses of ambroxol, specific histochemical examination techniques [27] detected a definite increase in surfactant synthesis, particularly in the cells exposed to acebrophylline [23].

2) Mucoregulating action

Acebrophylline has dual action on pathological secretions: it acts directly as a mucoregulator, and indirectly by stimulating surfactant synthesis.

**Direct activity:** investigations in animals have shown that ambroxol, as an ingredient of acebrophylline, can restore the normal viscosity of abnormal bronchial secretion [28]. This is not through any direct action on mucus already secreted [29, 30] but through its ability to “regulate” and “balance” bronchial secretions at the glandular level. After treatment with this compound, in fact, mucosal cysts may regress to normal glandular acini and mucus production by the serous glands may be activated. Acebrophylline thus promotes the production of “better quality” secretion.

**Indirect activity:** by stimulating the production of alveolar surfactant the viscosity of bronchial secretions is reduced. As regards a possible physico-chemical interaction between mucus and phospholipids [31], bronchial phospholipids appear to have a part in the formation of the fibrillary structure of mucus. To form the supraciliary colloidal “gel” secreted mucus must pass through two layers: the so-called “sol” and the layer of phospholipids or inter-sol-gel; this implies a physico-chemical interaction between the mucus and the surfactant molecules. This interaction can induce the formation of emulsified particles of mucus, with lower microviscosity.

3) Mucosecretory activity

In the rabbit and mouse, the acebrophylline’s activity on mucus was investigated by measuring the volume of bronchial secretion collected from the incannulated trachea, or by measuring the amount of phenol red secreted by the bronchial mucosa. In the tests with the dye, acebrophylline was more active than ambroxol alone, as confirmed by the amount secreted in relation to the 50% effective dose (ED50) needed to reach much the same result, which was considerably lower for acebrophylline (0.278 mM/kg p.o.) than ambroxol (0.498 mM/kg) [32].

4) Activity on mucociliary clearance (mucokinetic activity)

Acebrophylline’s mucokinetic activity was confirmed by investigating its ability to increase the transport of talc particles in a given time in the isolated rabbit trachea, and to increase the amount

---

**Fig. 2.** - Effect of acebrophylline and its single components on the uptake of labeled phospholipid precursors in rat BAL. (Modified from F Scaglione, GIMT (Suppl 1); 1992: 67-72)

**Fig. 3.** - Points of attack of acebrophylline and ambroxol on the synthesis of alveolar surfactant. (Modified from F Scaglione, GIMT (Suppl 1); 1992: 67-72)
ACEBROPHYLLINE: AN AIRWAY MUCOREGULATOR AND ANTI-INFLAMMATORY AGENT

of labeled fluorescein secreted and shifted into the trachea by the ciliary beats [32]. It is therefore quite possible that the stimulation of pulmonary surfactant by acebrophylline facilitates non-ciliary clearance as well, as the increase in surfactant eases transport of the secretions through the parts of the respiratory tract that have no cilia too [2]. The reduction in mucus adhesivity to the bronchial walls and its tendency to form smaller clumps when there is more surfactant certainly helps [2]. The expectorate from patients treated with acebrophylline has lower surface tension [32].

5) Antiinflammatory-antireactive activity

We have already mentioned that pulmonary surfactant and inflammatory mediators share phosphatidylcholine as their substrate. As acebrophylline partially inhibits phospholipase A [5] it can also inhibit the metabolism of phosphatidylincholine. In the bronchi this means less formation of the leukotrienes that cause inflammation and bronchoreactions. This was confirmed by the finding that in human mononuclear cells ambroxol, one of the components of acebrophylline, reduced the production of tumour necrosis factor (TNF), an inflammatory mediator, and the airway hyperresponsiveness induced by ozone in vivo in the dog [33, 34].

In the parenchyma the blockade of phospholipase A leaves a reserve of phosphatidylcholine that type II pneumocytes can use to re-synthesise surfactant (fig. 4). Scaglione et al. [4], using cultured human type II pneumocytes, studied the action of acebrophylline and its single components; they confirmed that only acebrophylline significantly reduced the production of LTB₄ leukotrienes, in favor of the surfactant constituents (table 1). Similarly, in vivo in rats pretreated with acebrophylline, and submitted to bronchial lavage at different times, leukotrienes LTC₄ and LTB₄ were reduced. The reduction in LTB₄ was particularly significant compared to untreated controls, further confirming acebrophylline’s antiinflammatory potential [4] (table 2).

By inhibiting the synthesis and release of inflammatory mediators, acebrophylline helps reduce bronchial edema secondary to inflammation, a key factor in airway obstruction, especially in chronic forms. The drug also has bronchodilating action, probably result-

![Fig. 4. - Effects on mucus and antiinflammatory action of acebrophylline.](Modified from G Cocco, GIMT (Suppl 1); 1992: 103-107)

### Table 1. - Effect of acebrophylline in vitro (10⁻⁴ mM) on the production of leukotrienes and phospholipids in pulmonary surfactant

<table>
<thead>
<tr>
<th>Treatment</th>
<th>LTC₄ (%) △</th>
<th>LTB₄ (%) △</th>
<th>Total phospholipids (ng/10⁷ cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>100 ± 1</td>
<td>100 ± 27</td>
<td>708 ± 17</td>
</tr>
<tr>
<td>Acebrophylline</td>
<td>95 ± 5</td>
<td>53 ± 5**</td>
<td>916 ± 21**</td>
</tr>
</tbody>
</table>

△ Percentage of controls (mean of three replicates); Cultured A549 cells; ** p≤ 0.01 acebrophylline vs. controls.

### Table 2. - Leukotrienes in BAL from rats treated with acebrophylline

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Leukotrienes △</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LTB₄ at 2 h</td>
</tr>
<tr>
<td>Control</td>
<td>100 ± 30</td>
</tr>
<tr>
<td>Acebrophylline</td>
<td>51 ± 3.5**</td>
</tr>
</tbody>
</table>

△ Percentage of controls (mean of three replicates); ** p≤ 0.01 acebrophylline vs. controls.
ing from its anti-inflammatory effect (with a consequent reduction in bronchial responsiveness).

These pharmacological activities constitute the basis for a correct therapeutic approach to acute and chronic obstructive airway diseases.

### Pharmacokinetics

In healthy volunteers, given 200 mg oral acebrophylline, the two components of the molecule - ambroxol and theophylline-7 acetic acid are released in the stomach and absorbed there and in the intestine, reaching optimal concentrations of ambroxol and very low levels of theophylline-7 acetic acid. Ambroxol reaches its peak in serum (mean $C_{\text{max}}$ 0.369 mcg/mL) at 2 hrs and theophylline-7 acetic acid after 1 hr (mean $C_{\text{max}}$ 0.008 mcg/mL). Thus it appears that the latter is either poorly absorbed or metabolised very fast and is eliminated in a fairly short time. Its low blood levels mean it is not likely to cause the untoward effects seen in man after theophylline, whose therapeutic window corresponds to much higher plasma concentrations (10-20 mcg/mL) [35, 36] (fig. 5).

Another factor in the excellent tolerability of acebrophylline is its pulmonary tropism [37]. The low plasma levels of the xanthine derivative are a further guarantee that there should be no interference with any other theophylline-based drug that might be used concomitantly.

Its stability in an acid environment, excellent tissue diffusion and fairly long half-life mean that acebrophylline need only be taken twice a day.

### Clinical pharmacology

As mentioned earlier, acebrophylline increases the synthesis and release of alveolar surfactant, resulting in triple action: mucoregulation, stimulation of bronchoalveolar clearance, and antiinflammatory-antireactive effect. In patients with chronic obstructive bronchitis, given the drug for 10-20 days, there was a good reduction in expectorate viscosity compared to baseline (between 53% and 78%) [38-41, 32] (table 3). Acting on both the production and transport of respiratory secretions, acebrophylline avoids the risk (presented by the “classical” mucolytics which have no activity on surfactant production and ciliary beats) of mucus accumulating even if it is fluid [38, 39].

On the basis of the complex relations between bronchial inflammation and hyperresponsiveness and surfactant production, Cocco et al. [24] performed a double-blind trial against placebo to assess the efficacy of acebrophylline, given for 30 days, in reducing aspecific bronchial hyperresponsiveness (ABH) in patients with clinically stable bronchial asthma. There was a mean increase of 86% in the PD$_{20}$ FEV$_1$ to metacholine challenge, compared to 32% in the control arm. These findings gain significance as the only drugs that had achieved a similar effect in the past.

---

### Table 3. Effect of acebrophylline (ACFA) on the rheology of bronchial secretions in humans

<table>
<thead>
<tr>
<th>Authors (method)</th>
<th>ACFA treatment</th>
<th>Units</th>
<th>Before (mean ± SD)</th>
<th>After (mean ± SD)</th>
<th>∆%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barthelemy [38] (bead viscometer)</td>
<td>syrup/cap-sules (200 mg/day x 20 days)</td>
<td>cm/sec</td>
<td>44.0 ± 13.55</td>
<td>153 ± 7.32</td>
<td>-55</td>
</tr>
<tr>
<td>Primbs [39] (bead viscometer)</td>
<td>capsules (200 mg/ day x 10 days)</td>
<td>cm/sec</td>
<td>38.0</td>
<td>8.2</td>
<td>-78</td>
</tr>
<tr>
<td>Weber [40] (bead viscometer)</td>
<td>capsules (200 mg/ day x 20 days)</td>
<td>cPs</td>
<td>410</td>
<td>152</td>
<td>-53</td>
</tr>
<tr>
<td>Agliati [41] (thread length)</td>
<td>sachets (200 mg/day x 14 days)</td>
<td>mm</td>
<td>25.6 ± 12.51</td>
<td>35.1 ± 8.59</td>
<td>+ 37.1</td>
</tr>
<tr>
<td>Allegra [42] (adhesiveness)</td>
<td>syrup (200 mg/day x 10 days)</td>
<td>dyn/cm</td>
<td>75.7 ± 8.1</td>
<td>51.3 ± 3.5</td>
<td>-32.2</td>
</tr>
</tbody>
</table>
were β2-agonists. A clinically significant reduction of ABH was recorded in seven out of ten patients after a single drug dose, and was still detectable 24h after the last dose at the end of the month’s treatment (fig. 6).

The fact that acebrophylline already changes ABH after acute administration, and influences its underlying mechanisms after longer treatment, together with its mucoregulating action, suggest it may prove useful in the treatment of asthma-like bronchitis.

Negative interference has been reported between theophylline and erythromycin and in animals simultaneous administration of theophylline together with erythromycin estolate at doses that alone are non-toxic enhanced the toxicity of the former, as indicated by the drastic drop in the LD50, i.e. the dose causing the death of half the animals [18]. In similar experimental conditions, acebrophylline was not affected by simultaneous use of erythromycin, and not only was there no reduction in the LD50 but in some cases it was actually higher, indicating the safety of the two components as regards their potential tolerability in patients [42].

Acebrophylline also limits the frequency of relapses of infection in patients with chronic obstructive lung disease (COLD) [43]. This is the result of the synergism of action between ambroxol and theophylline-7 acetic acid on surfactant production, which prevents bacteria adhering to the ciliate epithelium [44] and facilitates bronchoalveolar elimination [42] (fig. 7).

Clinical trials

Two early clinical trials compared the effectiveness of acebrophylline and ambroxol. Milvio et al. [45], in a double-blinded study, treated 41 patients between 30 and 80 years old, with acute or asthma-like bronchitis or flare-ups of chronic forms, with or without fever, increased bronchial secretion, cough and mucous, mucopurulent or purulent sputum. Patients were randomised to receive acebrophylline or ambroxol (both at 100 mg b.i.d.) for 20 days. At the end of this period there was a significant decrease in the amount of sputum in both groups; viscosity was also greatly reduced especially in the patients given acebrophylline. The two treatments relieved clinical symptoms similarly, but acebrophylline increased FEV1 by about 16%, significantly more than ambroxol.

Fracchia et al. [46] reported similar results from their controlled trial comparing acebrophylline (100 mg b.i.d.) and ambroxol (30 mg t.i.d.) in 38 patients with COLD, mean age 64.8 years. The two compounds gave similar improvements in mucous visco-elasticity, making it more fluid and easier to expel; this resulted in an improvement – already evident from the third day of treatment – in subjective and objective symptoms compared to baseline. However, after 14 days of treatment, only the patients assigned to acebrophylline showed a statistically significant increase of FEV1 and VC and a reduction of airway resistance (Raw) (fig. 8).

Similar findings come from subsequent studies on larger caselists. Catena et al. [43], in a multicentre, randomised, parallel-groups trial, enrolled 122 patients, mean age 54.6 years, with stable asthma-like chronic bronchitis, FEV1 between 50% and 80% of the expected value, and a positive broncho-reversibility test. Of these, 60 were treated with ambroxol (one 30-mg sachet t.i.d.), and the other 62 received acebrophylline (one 100-mg sachet b.i.d.) for 45 days. Acebrophylline was more active than ambroxol, in relieving clinical signs and symptoms (amount and appearance of sputum, pathological auscultation and dyspnea) and improving respirato-
ry function (VC, FEV₁ and forced expiratory flow, FEF₂₅₋₇₅) indicative of relief of obstruction; acebrophylline’s action was significantly superior to that of ambroxol, as a result of the stronger stimulation of pulmonary surfactant production and more effective mucoregulation. Acebrophylline also significantly reduced the frequency of bronchospastic attacks, the difference reaching significance between 15 and 30 days of treatment; during this period 21% of patients in the acebrophylline group and 54% taking ambroxol had at least one episode of bronchoconstriction. The picture improved further between 30 and 45 days of treatment, when the figures were respectively 5% and 44%. The mean number of bronchospastic episodes was also significantly lower in the acebrophylline patients (tables 4 and 5). Much the same findings were reported from a multicentre, non-controlled trial in 84 patients with asthma-like bronchitis given acebrophylline for 60 consecutive days [47].

In children with asthma-like bronchitis, acebrophylline was compared with ambroxol or a virtual placebo (multivitamin preparation), and the findings were similar to those in adults with the same illness. Fiocchi et al. [48] investigated 30 children with asthma-like bronchitis, aged 2-4 years; one group (16 patients) was given acebrophylline, 5 mL/day (50 mg), divided in two doses/day, and the other 14 patients were given 9 mL/day ambroxol (27 mg), in three doses/day. The children were treated for 21 days, followed by two weeks’ follow-up. Patients given acebrophylline experienced more prompt and more marked protection against bronchospasm than those given the ambroxol group. This was already evident from the first week, and was particularly striking in the last week of treatment (14-21 days), when none of the 16 children given acebrophylline suffered bronchospasm, compared to six in the ambroxol group (fig. 9). This improvement was reflected in the reduced need for β₂-agonists which was more marked in the acebrophylline group (table 6). Relief of symptoms, particularly those linked to the bronchospasm, was also different in the two groups. Acebrophylline acted sooner than ambroxol to improve pathological auscultation findings and relieve cough (fig. 10).

Another trial in 40 children with infectious asthma, treated with acebrophylline or placebo for 21 days, confirmed these findings [42].
ACEBROPHYLLINE: AN AIRWAY MUCOREGULATOR AND ANTI-INFLAMMATORY AGENT

Actions only in 6.5%. Generally the symptoms were mild and transient, and treatment had to be discontinued only in 0.7% of cases [49].

Conclusions

In all the trials comparing acebrophylline and ambroxol in patients with acute or asthma-like bronchitis, relapses of the chronic form [45] or COLD [46], acebrophylline has been more effective than ambroxol, achieving more marked improvement, though not significant, in the visco-elasticity of mucus, making it more fluid, thus easing expectoration. This means that there have been improvements in the subjective and objective symptoms starting by the third day of treatment [46]. However, patients treated with acebrophylline show significant improvements in measures of respiratory function. This might be due to the drug’s mechanism of action: its muco-regulating effect and the stimulation of pulmonary surfactant production and release, facilitates the drainage of bronchial secretions, leaving the airways more pervious.

The most important new element in the physiopathology of asthma-like bronchitis is the excessive airway hyper-responsiveness, partly resulting from inflammation, that is a fundamental factor of the disease. From the therapeutic point of view, this means using not only bronchodilators but also drugs that reduce the inflammation, hence also the ABH.

It thus appears that acebrophylline, given orally at the doses indicated for clinical use, reduces the hyper-responsive, inflammatory condition more markedly and more promptly than ambroxol. Among the parameters that showed greatest improvement, the incidence of broncho-spastic episodes is interesting, since they were significantly less frequent in patients receiving acebrophylline. It was also noted that while ambroxol gave relief of mild broncho-constriction, i.e. acting only, on patients with fewer episodes of bronchospasm, acebrophylline also provided a substantial benefit in more severe cases. These findings are in line with the latest international reports indicating that poor-quality, scant surfactant is one pathogenic factor of bronchospasm: therefore, drugs that stimulate surfactant production obviously help preventing this. It has also been suggested that there is a threshold for the optimal surfactant concentration in the airways. Below this threshold the surfactant only has muco-kinetic/muco-regulating activity, whereas above it

Safety in adults and children

Several trials in adults have confirmed that acebrophylline is well tolerated, with a low rate of adverse reactions, normally only mild gastrointestinal upset (2.6%) not requiring any treatment discontinuation, except as a precaution; no abnormalities have been reported in blood chemistry. The drug’s safety is further confirmed by the results in children. A post-marketing survey in more than 4000 children with acute bronchitis, either catarrhal, spastic or asthma-like, reported adverse reactions only in 6.5%. Generally the symptoms were mild and transient, and treatment had to be discontinued only in 0.7% of cases [49].

Table 6. - Number of doses of $\beta_2$-agonists (mean ± SD) required during treatment with acebrophylline (16 pts) and ambroxol (14 pts)

<table>
<thead>
<tr>
<th></th>
<th>After 7 days</th>
<th>After 21 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acebrophylline</td>
<td>14.4 ± 1.21</td>
<td>0</td>
</tr>
<tr>
<td>Ambroxol</td>
<td>20.4 ± 1.74</td>
<td>3.8 ± 4.91</td>
</tr>
</tbody>
</table>

Fig. 9. - Effects of acebrophylline and ambroxol on episodes of bronchoconstriction in children with bronchial asthma. ** = p<0.01 vs ambroxol.

Fig. 10. - Effects of acebrophylline and ambroxol on objective chest findings and cough in children with bronchial asthma. ** = p<0.01 vs ambroxol.

(Modified from A Fiocchi, Riv Infett Pediatr 1995; (10): 31-37.)

Fig. 10. - Effects of acebrophylline and ambroxol on objective chest findings and cough in children with bronchial asthma. ** = p<0.01 vs ambroxol.

(Modified from A Fiocchi, Riv Infett Pediatr 1995; (10): 31-37.)
– for instance, after stimulation with acetobryphyline – it also has antihistaminic activity [43]. The numerous trials in adults and children confirm the excellent safety profile of this compound, and the very low rate of adverse reactions.

References

3. Bashmakov YK, Bryuscina TS. The phospholipids of
4. Rensch H, Von Seefeld H. Surfactant-mucus interaction
6. Enhorning G. Asthma, a condition of surfactant defi-
7. Enhorning G. Asthma, a condition of surfactant defi-
9. Heath MF, Jacobson W. The inhibition of lysosomal phospholipase A from rabbit lung by ambroxol and its conse-
11. Ekelund L, Andersson K E, Enhorning G. Release of fe-
13. Kurashima K., Ogawa H, Ohka T. A pilot study of sur-
14. Collaborative group on antenatal steroid therapy: effect of antenatal dexamethasone administration on the pre-
17. Nobili A, Garattini S. Interazioni tra farmaci. I corti-
19. Luck L. Administration of corticoids to induce matu-
21. Coppi G, Silingardi S. Livelli plasmatici, parametri far-
27. Bracco M, Curti PC. Beschreibung einer histochemi-
28. Noack W, Elbrecht B. Elektronenmikroskopische un-
29. Allegra L, Bossi R, Braga P C, Allegra L, ed. Drugs in Bronchial Mucolo-
30. Shimura S, Okubo T, Maeda S, et al. Effect of expecto-
32. Scaglione F, Dugnani S, Maccarinelli G, et al. Ambroxol in-
34. Chitano P, Di Stefano A, Finotto S, et al. Ambroxol inhib-
35. D’Angelo L. Livelli plasmatici e parametri farmacoci-
36. Sved S, McGilveray IJ, Beaudoin N. The assay and ab-
37. Mezzetti M, Colombo L. A pharmacokinetic study on
38. Barthelemy F. Le theophillinaacetate d’ambroxol dans
41. Post M, Batenburg J J, Schunmans E A, et al. The perf-
43. Bracco M, Curti PC. Beschreibung einer histochemi-
44. Noack W, Elbrecht B. Elektronenmikroskopische un-
45. Shimura S, Okubo T, Maeda S, et al. Effect of expecto-
47. Scaglione F, Dugnani S, Maccarinelli G, et al. Ambroxol in-
51. Post M, Batenburg J J, Schunmans E A, et al. The perf-
53. Bracco M, Curti PC. Beschreibung einer histochemi-
54. Noack W, Elbrecht B. Elektronenmikroskopische un-
55. Shirmura S, Okubo T, Maeda S, et al. Effect of expecto-
58. Bianchi M, Mantovani A, Erroi A et al. Ambroxol inhib-
61. Post M, Batenburg J J, Schunmans E A, et al. The perf-
63. Bracco M, Curti PC. Beschreibung einer histochemi-
64. Noack W, Elbrecht B. Elektronenmikroskopische un-
65. Shimura S, Okubo T, Maeda S, et al. Effect of expecto-
68. Bianchi M, Mantovani A, Erroi A et al. Ambroxol inhib-